Nabil Saba, MD
Medical Oncology · Atlanta, GANPI 1558479188
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $149,547 of the $224,880 with a category attached, or 66.5%. 26 manufacturers reported payments, led by Merck at 31.0% of the total. 2025 is the largest year on record at $88,649, 3.6 times the $24,837 reported in 2019. Among medical oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $1330.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$70K
- Dr.reddy's Laboratories,inc.$33K
- GSK$27K
- Exelixis Inc.$26K
- EMD Serono Research & Development Institute, Inc.$11K
- Eisai Inc.$11K
- plus $46K from 20 others
Across 186 payments — averaging $14,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.3M
- Biontech SE$414K
- AVEO Pharmaceuticals, Inc.$281K
- Exelixis Inc.$186K
- Merck$129K
- AstraZeneca$117K
- plus $204K from 8 others
What the payments were for
- Consulting fees$149,54767%
- Speaking & faculty fees$6,9003%
- Travel & lodging$64,10129%
- Food & beverage$4,2642%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 63 | $69,716 |
| Dr.reddy's Laboratories,inc. | 9 | $33,048 |
| GSK | 25 | $27,403 |
| Exelixis Inc. | 18 | $26,319 |
| EMD Serono Research & Development Institute, Inc. | 2 | $11,250 |
| Eisai Inc. | 5 | $11,020 |
| Merck Kgaa | 3 | $9,063 |
| Coherus Oncology, Inc. | 5 | $5,621 |
| Pfizer | 5 | $5,560 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,491 |
| Seagen Inc. | 3 | $3,548 |
| Janssen Scientific Affairs, LLC | 2 | $3,173 |
| Precigen, Inc. | 1 | $2,250 |
| Janssen Global Services, LLC | 4 | $2,248 |
| Janssen Research & Development, LLC | 1 | $2,115 |
| Novartis | 1 | $2,000 |
| Astrazeneca UK Limited | 3 | $1,849 |
| Biontech SE | 6 | $1,585 |
| AVEO Pharmaceuticals, Inc. | 2 | $875 |
| Johnson & Johnson | 1 | $705 |
| Urogen Pharma, Inc. | 1 | $640 |
| Gilead | 1 | $133 |
| Roche Products Limited | 1 | $100 |
| Regeneron | 1 | $79 |
| AstraZeneca | 1 | $68 |
| Tempus AI, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$224,880 in reported general payments places this provider in the 95th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 51 | $853,246 |
| TafinlarDabrafenib Mesylate | 51 | $709,463 |
| LenvimaLenvatinib Mesylate | 28 | $666,277 |
| CabometyxCabozantinib S-Malate | 23 | $575,656 |
| CaprelsaVandetanib | 11 | $199,489 |
| VerzenioAbemaciclib | 19 | $167,745 |
| Ondansetron Hcl | 101 | $1,755 |
| Naloxone Hcl | 16 | $1,128 |
| Prochlorperazine Maleate | 83 | $644 |
| Dexamethasone | 80 | $595 |
| Lidocaine Hcl ViscousLidocaine Hcl | 20 | $306 |
| Clindamycin Phosphate | 14 | $303 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $223 |
| Ondansetron OdtOndansetron | 16 | $149 |
| Oxycodone Hcl | 16 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMekinist, Tafinlar | $2,000 | $1,562,709102 claims |
| Eisai Inc.Lenvima | $11,020 | $666,27728 claims |
| Exelixis Inc.Cabometyx | $26,319 | $575,65623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Atlanta
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Erin DunbarAtlanta$35K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
- Ruth SacksAtlanta$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.